Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings

Abstract Purpose This study was designed to identify a useful clinical parameter or model for prostate biopsy in surgery-indicated benign prostate hyperplasia (BPH) patients with elevated PSA levels and negative multiparametric prostate magnetic resonance imaging (MRI) results. Patients and methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Yiji Peng, Chengcheng Wei, Ying Li, Fuhan Zhao, Yuan Liu, Tao Jiang, Zhipeng Chen, Jun Zheng, Jiong Fu, Peng Wang, Wenhao Shen
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Urology
Subjects:
Online Access:https://doi.org/10.1186/s12894-025-01719-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850027927552393216
author Yiji Peng
Chengcheng Wei
Ying Li
Fuhan Zhao
Yuan Liu
Tao Jiang
Zhipeng Chen
Jun Zheng
Jiong Fu
Peng Wang
Wenhao Shen
author_facet Yiji Peng
Chengcheng Wei
Ying Li
Fuhan Zhao
Yuan Liu
Tao Jiang
Zhipeng Chen
Jun Zheng
Jiong Fu
Peng Wang
Wenhao Shen
author_sort Yiji Peng
collection DOAJ
description Abstract Purpose This study was designed to identify a useful clinical parameter or model for prostate biopsy in surgery-indicated benign prostate hyperplasia (BPH) patients with elevated PSA levels and negative multiparametric prostate magnetic resonance imaging (MRI) results. Patients and methods We retrospectively analyzed clinical and pathological data from patients who were diagnosed with BPH and admitted to the inpatient department for surgery between January 2010 and September 2020. Clinical data, including age, prostate specific antigen (PSA) level, F/T PSA ratio, prostate volume, and PSA density (PSAD), were used for comprehensive analysis. Univariate and multivariate logistic regression analyses were performed to develop a predictive model. Receiver operating characteristic (ROC) analysis and decision curve analysis (DCA) were performed to assess the diagnostic value of the predictive model, PSA concentration, F/T PSA ratio and PSAD. Results A total of 318 patients were included in the study, 8.2% (26/318) of whom were histologically diagnosed with prostate cancer (PCa). Univariate and multivariate logistic regression analyses revealed that PSAD was the only independent predictor of PCa biopsy. ROC curve analysis of PCa detection revealed a larger area under the curve (AUC) for the predictive model (AUC 0.855) and for PSAD (AUC 0.848) than for PSA (AUC 0.722) or the F/T PSA ratio (AUC 0.635). DCA demonstrated that the optimal strategy would be to restrict biopsies to men with a PSAD of 0.30 ng/ml/cm3. Conclusions Our study suggested that for BPH patients with surgical indications who present with PSA abnormalities and negative imaging findings, the use of a new PSAD threshold of 0.30 ng/ml/cm3 could facilitate convenient and sound biopsy decisions. This approach could reduce the complications and length of hospital stay associated with biopsies and reduce hospital costs.
format Article
id doaj-art-ebd2afc31f24438a831d718bd4c9baec
institution DOAJ
issn 1471-2490
language English
publishDate 2025-03-01
publisher BMC
record_format Article
series BMC Urology
spelling doaj-art-ebd2afc31f24438a831d718bd4c9baec2025-08-20T02:59:59ZengBMCBMC Urology1471-24902025-03-012511910.1186/s12894-025-01719-5Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findingsYiji Peng0Chengcheng Wei1Ying Li2Fuhan Zhao3Yuan Liu4Tao Jiang5Zhipeng Chen6Jun Zheng7Jiong Fu8Peng Wang9Wenhao Shen10Department of Urology, Southwest Hospital, Army Medical University, (Third Military Medical University)Department of Urology, Chongqing public health medical centerCenter for Medical Big Data and Artificial Intelligence, Southwest Hospital, Army Medical University, (Third Military Medical University)Department of Urology, Southwest Hospital, Army Medical University, (Third Military Medical University)Department of Urology, Southwest Hospital, Army Medical University, (Third Military Medical University)Department of Urology, Southwest Hospital, Army Medical University, (Third Military Medical University)Department of Urology, Southwest Hospital, Army Medical University, (Third Military Medical University)Department of Urology, Southwest Hospital, Army Medical University, (Third Military Medical University)Department of Urology, Southwest Hospital, Army Medical University, (Third Military Medical University)Center for Medical Big Data and Artificial Intelligence, Southwest Hospital, Army Medical University, (Third Military Medical University)Department of Urology, Southwest Hospital, Army Medical University, (Third Military Medical University)Abstract Purpose This study was designed to identify a useful clinical parameter or model for prostate biopsy in surgery-indicated benign prostate hyperplasia (BPH) patients with elevated PSA levels and negative multiparametric prostate magnetic resonance imaging (MRI) results. Patients and methods We retrospectively analyzed clinical and pathological data from patients who were diagnosed with BPH and admitted to the inpatient department for surgery between January 2010 and September 2020. Clinical data, including age, prostate specific antigen (PSA) level, F/T PSA ratio, prostate volume, and PSA density (PSAD), were used for comprehensive analysis. Univariate and multivariate logistic regression analyses were performed to develop a predictive model. Receiver operating characteristic (ROC) analysis and decision curve analysis (DCA) were performed to assess the diagnostic value of the predictive model, PSA concentration, F/T PSA ratio and PSAD. Results A total of 318 patients were included in the study, 8.2% (26/318) of whom were histologically diagnosed with prostate cancer (PCa). Univariate and multivariate logistic regression analyses revealed that PSAD was the only independent predictor of PCa biopsy. ROC curve analysis of PCa detection revealed a larger area under the curve (AUC) for the predictive model (AUC 0.855) and for PSAD (AUC 0.848) than for PSA (AUC 0.722) or the F/T PSA ratio (AUC 0.635). DCA demonstrated that the optimal strategy would be to restrict biopsies to men with a PSAD of 0.30 ng/ml/cm3. Conclusions Our study suggested that for BPH patients with surgical indications who present with PSA abnormalities and negative imaging findings, the use of a new PSAD threshold of 0.30 ng/ml/cm3 could facilitate convenient and sound biopsy decisions. This approach could reduce the complications and length of hospital stay associated with biopsies and reduce hospital costs.https://doi.org/10.1186/s12894-025-01719-5PSA densityProstate MRIProstate biopsyBenign prostate hyperplasiaProstate cancer
spellingShingle Yiji Peng
Chengcheng Wei
Ying Li
Fuhan Zhao
Yuan Liu
Tao Jiang
Zhipeng Chen
Jun Zheng
Jiong Fu
Peng Wang
Wenhao Shen
Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
BMC Urology
PSA density
Prostate MRI
Prostate biopsy
Benign prostate hyperplasia
Prostate cancer
title Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
title_full Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
title_fullStr Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
title_full_unstemmed Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
title_short Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
title_sort optimal psa density threshold for prostate biopsy in benign prostatic obstruction patients with elevated psa levels but negative mri findings
topic PSA density
Prostate MRI
Prostate biopsy
Benign prostate hyperplasia
Prostate cancer
url https://doi.org/10.1186/s12894-025-01719-5
work_keys_str_mv AT yijipeng optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT chengchengwei optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT yingli optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT fuhanzhao optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT yuanliu optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT taojiang optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT zhipengchen optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT junzheng optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT jiongfu optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT pengwang optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings
AT wenhaoshen optimalpsadensitythresholdforprostatebiopsyinbenignprostaticobstructionpatientswithelevatedpsalevelsbutnegativemrifindings